Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy.
The first and second Medical Research Council UKALL trials have shown that alteration in the timing of methotrexate and 6-mercaptopurine maintenance therapy for the treatment of acute lymphoblastic leukaemia can markedly change drug induced toxicity. Maintenance chemotherapy in both trials used a similar total dosage of these drugs but the timing of their administration was different in the two schedules.
D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000401:mortality; D007958:Leukocyte Count; D008214:Lymphocytes; D008231:Lymphopenia / Q000139:chemically induced; D015122:Mercaptopurine / Q000627:therapeutic use* / Q000633:toxicity; D008727:Methotrexate / Q000627:therapeutic use* / Q000633:toxicity; D009503:Neutropenia / Q000139:chemically induced; D009504:Neutrophils; D012075:Remission, Spontaneous; D013997:Time Factors
D015122:Mercaptopurine; D008727:Methotrexate